



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com <http://www.wjgnet.com>

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6935

**Title:** MiRNA as potential biomarkers for gastric cancer

**Reviewer code:** 01939897

**Science editor:** Huan-Huan Zhai

**Date sent for review:** 2013-11-01 12:20

**Date reviewed:** 2013-11-01 16:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

The name of the countries where the report came from in the tables will be helpful for the readers. The demographic features are obvious in gastric cancer as you know. Naturally, Chinese are dominant, but Korea and Japan could be different.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6935

**Title:** MiRNA as potential biomarkers for gastric cancer

**Reviewer code:** 02537773

**Science editor:** Huan-Huan Zhai

**Date sent for review:** 2013-11-01 12:20

**Date reviewed:** 2013-11-07 20:32

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input checked="" type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input checked="" type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

In the present review the authors provide some light view on the existing data to potential of miRNAs in gastric cancer. Indeed, there is a need of objective view of this still very new and preliminary topic, therefore this manuscript may be of the interest. However, I have a number of critical issues. The manuscript is in present form not sufficiently objective. Unfortunately, there are at present no high quality data to confirm any kind of proof-of-principle data in independent cohorts in comparison to available techniques. Further, despite of the hope of many miRNA researchers, we still do not know if miRNA will ever enhance the sensitivity/specificity for gastric cancer diagnosis, as it has not been tested before. This needs to be clearly stated. Both in Abstract and Main manuscript the authors state that miRNA could detect the gastric cancer at early stage. Here, it is important to differentiate between could detect vs. showed different expression. Extended revision is necessary. The introduction to the topic of gastric cancer is very preliminary. The problem of gastric cancer and main methodological, clinical and diagnostic uniqueness of this tumor has not been taken to account. Here, the authors should substantially expand the introduction and provide state of the art knowledge (guidelines etc.). The statement in the paragraph 1 of the Introduction that combined use of tumor markers such as AFP, CEA, CA125 and CA19-9 improves the sensitivity is of no value by biomarker performance of (4-20%). None of available biomarkers is recommended for gastric cancer diagnosis. Further comments: 1) Basic conditions for biomarker utility are not presented. 2) Role of miRNA in gastric carcinogenesis is not adequately presented using in vitro studies. 3) Strong support in clinical application of miRNA remains to be provided. 4) Different parts of the manuscript are repeated in different section of the manuscript (for example miR-125-5p). 5) Table is



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com) <http://www.wjgnet.com>

---

not easy to follow. Separate presentation of the different functions might be more informative. In the table - the method of data normalization is missing. This is of the great value as the most of the studies used RNU6b for blood specimens, which is one of the most unreliable blood normalizers currently available. Overall the presentation of the sample number confusing. 6) Conclusion and future perspectives are unfocused and are mixed with different data to expl gastric juice miRNAs and limitation. I would recommend splitting it into at least 3 sections. 7) Language needs substantial editing!



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com <http://www.wjgnet.com>

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6935

**Title:** MiRNA as potential biomarkers for gastric cancer

**Reviewer code:** 00050080

**Science editor:** Huan-Huan Zhai

**Date sent for review:** 2013-11-01 12:20

**Date reviewed:** 2013-12-13 17:59

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Recently, miRNA is come under the spotlight not only gastric cancer but also various kind of disease. This review is well written and this manuscript gives much informations to readers



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6935

**Title:** MiRNA as potential biomarkers for gastric cancer

**Reviewer code:** 00033010

**Science editor:** Huan-Huan Zhai

**Date sent for review:** 2013-11-01 12:20

**Date reviewed:** 2014-03-02 15:44

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

The paper of Hanshao Liu et al “MicroRNAs as potential biomarkers for gastric cancer” is a parade of the principal miRNAs involved in gastric cancer. The possibility that these molecules could be in the future a diagnostic marker is detailed. However, the large amount of data in this field, and the researches often conflicting in the literature may be a limit in this topic. Main remarks: ? “GC remains the most frequent type of cancer worldwide” this statement is not true: the most frequent type of cancer is lung cancer in males and breast cancer in females. Furthermore, the statement does not agree with the message of the corresponding reference (n.1) ? A figure summarizing main miRNAs and carcinogenetic pathways may render the manuscript more appealing ? Authors treat the possibility of “miRNA-based therapeutic approaches”. However, they report only how classic anticancer therapy (vincristine) may influence miRNA expression. Have new drugs targeted against specific miRNAs been investigated? The answer to this question must be detailed. ? A final observation: thousands of miRNA have been demonstrated to be related to gastric cancer. Therefore, the analysis of a single miRNA could be neither specific nor sensitive. For this reason only the combination of several miRNA could be effective for diagnostic purpose. This aspect must be emphasized in the final discussion with the possible implications for clinical practice and cost/benefit aspect.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6935

**Title:** MiRNA as potential biomarkers for gastric cancer

**Reviewer code:** 01588319

**Science editor:** Huan-Huan Zhai

**Date sent for review:** 2013-11-01 12:20

**Date reviewed:** 2014-03-07 18:54

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Minor issues: 1.How about the histological types of gastric cancer of these published literatures in this review? 2.The variable, "function" should be replaced by "clinical application". 3.The pattern of subheadings should be consistent, eg. italic, upper-/lower-case...